New Two-Pronged cancer drug begins first human testing
NCT ID NCT07274813
Summary
This is a first-in-human study to test the safety and side effects of a new experimental drug called HLX37 in adults with advanced solid tumors that have spread or stopped responding to standard treatments. The drug is designed to attack cancer in two ways at once by targeting two different proteins (PD-L1 and VEGF) involved in tumor growth. The study will first test HLX37 alone, and then test it in combination with standard chemotherapy for a specific type of lung cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Second Affiliated Hospital of Air Force Medical University of the People's Liberation Army of China
RECRUITINGXi'an, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.